Barclays
CADL icon

Barclays’s Candel Therapeutics CADL Stock Holding History

Barclays’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$406K Buy
39,440
+27,741
+237% +$210K ﹤0.01% 3335
2026
Q1 		$57.3K Sell
11,699
-57,645
-83% -$314K ﹤0.01% 4266
2025
Q4 		$392K Buy
69,344
+9,749
+16% +$52.4K ﹤0.01% 3983
2025
Q3 		$304K Sell
59,595
-8,841
-13% -$51.1K ﹤0.01% 4089
2025
Q2 		$346K Buy
68,436
+37,114
+118% +$191K ﹤0.01% 3969
2025
Q1 		$177K Sell
31,322
-2,995
-9% -$24.5K ﹤0.01% 4124
2024
Q4 		$298K Buy
34,317
+5,629
+20% +$33.3K ﹤0.01% 4125
2024
Q3 		$199K Buy
28,688
+21,971
+327% +$136K ﹤0.01% 4293
2024
Q2 		$41.6K Buy
+6,717
New +$50.4K ﹤0.01% 4277

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's CADL Position: Q2 2026 in Review

Barclays increased its Candel Therapeutics (CADL) stake by 237% in Q2 2026, buying an estimated $210K and bringing the position to 39,440 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #3335.

Barclays first reported a position in CADL in Q2 2024 and has held it in 9 quarters since. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Barclays held 39,440 shares of Candel Therapeutics worth $406K as of Q2 2026.
  • Barclays bought 27,741 Candel Therapeutics shares in Q2 2026, an estimated $210K.
  • Candel Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3335 holding.
  • Barclays first reported a position in Candel Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.